*** On mobile devices , use left and right swipe gestures to view whole agenda
| Time | Session | Target Selection & Validation | Hit Identification | Lead Optimization | Early ADME/Tox | AI in Drug Discovery |
|---|---|---|---|---|---|---|
| 8:00 – 8:30 | Registration & Welcome Coffee | |||||
| 8:30 – 9:00 | Welcome & Keynote Presentation Next-Gen Small Molecule Innovation: Unlocking Complex Targets with Confidence | |||||
| Breakout Sessions | ||||||
| 9:05 – 10:05 | Session 1 | Target Selection & Validation Overcoming the challenge of targeting protein-protein interactions in undruggable space | Hit Identification Improving hit rates: Emerging strategies in fragment-based and DNA-encoded library screening | Lead Optimization Striking the balance between potency, solubility, and metabolic stability | Early ADME/Tox in Drug Discovery Predicting human pharmacokinetics earlier: Reducing late-stage failures | AI in Drug Discovery Data quality crisis: Why AI models fail without clean, structured chemistry data |
| Moderator | ||||||
| 10:10 – 10:40 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | |||||
| 10:40 – 11:10 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | |||||
| 11:10 – 11:20 | Refreshment Break | |||||
| 11:20 – 12:20 | Session 2 | Target Selection & Validation Using omics and CRISPR tools to validate high-confidence small molecule targets | Hit Discovery Integrating AI/ML with HTS platforms to accelerate hit identification | Lead Optimization Predicting and managing off-target effects during lead optimization | Early ADME/Tox in Drug Discovery Metabolism & stability challenges: Designing molecules that survive the body | AI in Drug Discovery AI for de novo design: Overcoming the gap between generated molecules and synthesizable reality |
| Moderator | ||||||
| 12:20 – 13:20 | Lunch | |||||
| 13:25 – 13:55 | Spotlight Presentation Discovery of a First-in-Class Oral Inhibitor for a CNS Target | |||||
| 14:00 – 14:30 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | |||||
| 14:30 – 15:00 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | |||||
| 15:00 – 15:10 | Refreshment Break | |||||
| 15:10 – 15:40 | Session 3 | Case Study - Target Selection & Validation Leveraging single-cell transcriptomics for target identification in oncology | Case Study - Hit Discovery Miniaturized assays for ultra-high-throughput fragment screening | Case Study - Lead Optimization Physicochemical profiling and optimization for oral bioavailability | Case Study - Early ADME/Tox Early safety flags: Identifying hERG, off-targets, and cytotoxicity before it's too late | AI in Drug Discovery Closing the loop: Challenges in building autonomous, AI-driven discovery pipelines |
| Moderator | ||||||
| 15:45 – 16:45 | Session 4 | Target Selection & Validation Leveraging single-cell transcriptomics for target identification in oncology | Hit Discovery Miniaturized assays for ultra-high-throughput fragment screening | Lead Optimization Physicochemical profiling and optimization for oral bioavailability | Early ADME/Tox in Drug Discovery Bridging the translation gap: Connecting in vitro potency to in vivo efficacy | AI in Drug Discovery Trust & interpretability: Making AI predictions actionable for chemists |
| Moderator | ||||||
| 16:45 – 17:45 | Evening Networking Reception | |||||
